Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly ...
Low baseline 25 (OH)D levels are associated with higher mortality and cardiovascular event risks among patients with systemic lupus erythematosus (SLE), with evidence of a U-shaped relationship ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback